Advantages and Disadvantages of Car-T Therapy in the Clinical Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Chimeric antigen receptor T-cell (CAR-T) therapy is a new innovative cancer treatment. In recent years, many clinical studies have demonstrated its efficacy in the treatment of DLBCL. Compared to many existing cancer treatments, CAR-T therapy offers many advantages. For example, unique specificity and excellent efficacy in patients with refractory and recurrent tumors. This article focuses on the application of CAR-T in the treatment of DLBCL and analyzes the advantages and disadvantages of this therapy from multiple perspectives. The advantages of CAR-T therapy are discussed in three aspects: CAR-T for relapsed and chemotherapy-resistant patients, CAR-T cell’s distinctive specificity and ideal treatment outcome. Then, the three most representative limitations of CAR-T therapy are analyzed in this article: antigen escape, antigen-positive relapse, and toxicities. Finally, the article points out the promising future of CAR-T therapy.